ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 130 filers reported holding ASCENDIS PHARMA A/S in Q3 2019. The put-call ratio across all filers is 0.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $49,331,000 | -61.7% | 375,000 | -62.5% | 0.20% | -68.6% |
| Q1 2021 | $128,880,000 | -22.7% | 1,000,000 | 0.0% | 0.64% | -36.2% |
| Q4 2020 | $166,780,000 | -13.5% | 1,000,000 | -20.0% | 1.00% | -24.8% |
| Q3 2020 | $192,900,000 | +14.4% | 1,250,000 | +9.6% | 1.33% | -1.1% |
| Q2 2020 | $168,606,000 | +8.8% | 1,140,000 | -17.2% | 1.35% | +1.4% |
| Q1 2020 | $154,991,000 | -12.9% | 1,376,349 | +7.6% | 1.33% | +10.7% |
| Q4 2019 | $177,934,000 | +19.2% | 1,279,000 | -17.5% | 1.20% | +6.5% |
| Q3 2019 | $149,296,000 | -15.8% | 1,550,000 | +0.6% | 1.13% | -2.2% |
| Q2 2019 | $177,331,000 | +0.4% | 1,540,000 | +2.7% | 1.15% | -13.2% |
| Q1 2019 | $176,550,000 | +88.0% | 1,500,000 | +0.0% | 1.33% | +92.7% |
| Q4 2018 | $93,931,000 | -9.0% | 1,499,297 | +2.9% | 0.69% | +13.0% |
| Q3 2018 | $103,264,000 | +6.5% | 1,457,297 | 0.0% | 0.61% | +1.8% |
| Q2 2018 | $96,939,000 | +15.2% | 1,457,297 | +13.2% | 0.60% | +2.7% |
| Q1 2018 | $84,157,000 | – | 1,286,800 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |